(Alliance News) - Scancell Holdings PLC on Wednesday said it has appointed Ursula Ney as a non-executive director with immediate effect, replacing Matthew Frohn who is standing down on Thursday next week.
The immunotherapies developer said Ney has over thirty years' experience in the pharmaceutical and biotechnology industry, including twenty years in senior leadership roles. Most recently, she was chief executive officer of French biopharmaceutical company Genkyotex SA. She is currently a non-executive director of science research company Proteome Sciences PLC.
"I am pleased to welcome Ursula to the board of Scancell. Ursula's extensive late stage development experience in the biotech sector will be invaluable as the company continues to develop its product pipeline," said Chair John Chiplin.
Scancell shares were untraded in London on Wednesday, last closing at 5.72 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
Proteome (PRM)
Scancell Holdings (SCLP)